Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Day Two At BIO CEO: Deal Value Up, Deal Volume Down

This article was originally published in The Pink Sheet Daily

Executive Summary

The Let’s Make a Deal panel looked forward to more big product-focused Genzyme/Alnylam type deals in 2014 in a deal landscape changed by a robust pubic market and by caution on the part of big pharma; BIO chair Rachel King on 2014 priorities; Stallergenes prepares to launch Oralair

You may also be interested in...



Riding High On Investor Enthusiasm, BIO CEO 2014 Opens In New York

Sanofi’s Chris Viehbacher says mutual respect, cultural understanding and close communication are keys to relationships with partners Alnylam and Regeneron; BIO survey confirms investor optimism for 2014; and RNAi panelists reflect on recent IPO glories.

Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

Moderna CEO Pushes Back On Trump Debate Comments On COVID Vaccine, Offers Own Timeline

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel